Actavis (NYSE: ACT) is a unique specialty pharmaceutical company focused on developing, manufacturing and commercializing high quality affordable generic and innovative branded pharmaceutical products for patients around the world.

The Company has global headquarters in Dublin, Ireland and U.S. Administrative Headquarters in Parsippany, New Jersey, USA.

Actavis markets a broad portfolio of branded and generic pharmaceuticals and develops innovative medicines for patients suffering from diseases principally in the central nervous system, gastroenterology, women’s health, urology, cardiovascular, respiratory and anti-infective therapeutic categories.
Actavis markets approximately 1000 generic, branded generic, established brands and Over-the-Counter (OTC) pharmaceutical products globally through operations in more than 60 countries.
The Company is an industry leader in product research and development, with one of the broadest brand development pipelines in the pharmaceutical industry, and a leading position in the submission of generic product applications. Actavis has commercial operations in more than 60 countries and operates more than 30 manufacturing and distribution facilities around the world.

Publications show all

Actavis Pharma has published 59 articles.

Patents show all


Clinical Trials show all

193N/A159Phase 3147Phase 4110Phase 2104Phase 127Other

SEC Filings show all


Contact Information